Tag: CodeBreaK 300 clinical trial

Home / CodeBreaK 300 clinical trial

Categories

Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer

On January 16, 2025, the Food and Drug Administration sanctioned the use of sotorasib (Lumakras, Amgen Inc.) in conjunction with panitumumab (Vectibix, Amgen Inc.) for adult patients diagnosed with KR...
codebreak-300-clinical-trial

Scan the code